All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 166 points (-1.0%) at 16,455 as of Tuesday, Feb. 23, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 990 issues advancing vs. 1,939 declining with 142 unchanged.

The Drugs industry currently sits down 1.5% versus the S&P 500, which is down 0.9%. On the negative front, top decliners within the industry include

PTC Therapeutics

(

PTCT

), down 50.8%,

Jazz Pharmaceuticals

(

JAZZ

), down 3.2%,

Incyte

(

INCY

), down 3.0%,

Vertex Pharmaceuticals

(

VRTX

), down 2.5% and

Shire

(

SHPG

), down 1.4%. Top gainers within the industry include

Valeant Pharmaceuticals International

(

VRX

), up 8.2%,

Perrigo

(

PRGO

), up 2.0% and

Mylan

(

MYL

), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Celgene

(

CELG

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Celgene is down $0.74 (-0.7%) to $103.84 on light volume. Thus far, 2.3 million shares of Celgene exchanged hands as compared to its average daily volume of 6.1 million shares. The stock has ranged in price between $103.33-$105.73 after having opened the day at $104.25 as compared to the previous trading day's close of $104.58.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. Celgene has a market cap of $80.2 billion and is part of the health care sector. Shares are down 12.7% year-to-date as of the close of trading on Monday. Currently there are 14 analysts that rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Johnson & Johnson

(

JNJ

) is down $0.62 (-0.6%) to $104.13 on light volume. Thus far, 2.4 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.3 million shares. The stock has ranged in price between $103.96-$104.79 after having opened the day at $104.65 as compared to the previous trading day's close of $104.75.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $288.2 billion and is part of the health care sector. Shares are up 2.0% year-to-date as of the close of trading on Monday. Currently there are 8 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, expanding profit margins and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Johnson & Johnson Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is down $0.71 (-0.8%) to $88.39 on light volume. Thus far, 2.5 million shares of Gilead exchanged hands as compared to its average daily volume of 11.7 million shares. The stock has ranged in price between $87.90-$89.40 after having opened the day at $89.10 as compared to the previous trading day's close of $89.10.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $126.0 billion and is part of the health care sector. Shares are down 11.9% year-to-date as of the close of trading on Monday. Currently there are 12 analysts that rate Gilead a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).